Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REC-4881 in Solid Tumors With AXIN1 or APC Mutation
NCT06005974Phase 2Terminated
- Sponsor
- Recursion Pharmaceuticals
- Start
- Jan 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TAK-733 in solid tumor, sponsored by Recursion Pharmaceuticals. Started Jan 2024; status: terminated.
02
Drugs
TAK-733
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06005974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06005974.